<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00273429</url>
  </required_header>
  <id_info>
    <org_study_id>PRN 04-015</org_study_id>
    <nct_id>NCT00273429</nct_id>
  </id_info>
  <brief_title>Cosopt Versus Xalatan</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmaceutical Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmaceutical Research Network</source>
  <brief_summary>
    <textblock>
      To compare the 24-hour efficacy and safety, measured every three hours, of the
      dorzolamide/timolol fixed combination given twice daily versus latanoprost and placebo each
      given once daily.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date>December 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Open-Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>timolol maleate 0.5%</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dorzolamide/timolol maleate fixed combination</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>latanoprost 0.005%</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adults with primary open-angle, pigmentary, or exfoliation glaucoma, or ocular
             hypertenstion

          -  intraocular pressure should be 22 to 30 mm Hg inclusive on timolol BID at the 08:00 H

          -  ETDRS visual acuity must be 1.0 or better in both eyes

        Exclusion Criteria:

          -  any contraindications to study medications

          -  any anticipated change in systemic hypertensive therapy during the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William C. Stewart, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pharmaceutical Research Network, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jay Mulaney, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Florida Eye Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sriram Sonty, MD, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Midwest Eye Center SC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Florida Eye Associates</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Eye Center SC</name>
      <address>
        <city>Bourbonnais</city>
        <state>Illinois</state>
        <zip>60914</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2006</study_first_submitted>
  <study_first_submitted_qc>January 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2006</study_first_posted>
  <last_update_submitted>January 8, 2007</last_update_submitted>
  <last_update_submitted_qc>January 8, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
    <mesh_term>Dorzolamide</mesh_term>
    <mesh_term>Maleic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

